Comvax (Haemophilus b Conjugate and Hepatitis B Vaccine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 13, 2022 Category: Drugs & Pharmacology Source Type: news

The FDA Just Authorized the First COVID-19 Pill, a Pfizer Drug That Can Be Taken At Home
U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus. The long-awaited milestone comes as U.S. cases, hospitalizations and deaths are all rising and health officials warn of a tsunami of new infections from the omicron variant that could overwhelm hospitals. The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited. All of the previously authorized drugs against the disease require an IV or an injection. [time-brightcove not-...
Source: TIME: Health - December 22, 2021 Category: Consumer Health News Authors: MATTHEW PERRONE / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news

PreHevbrio (Hepatitis B Vaccine (Recombinant) Injectable Suspension) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 20, 2021 Category: Drugs & Pharmacology Source Type: news

New Hepatitis B Vaccination Recommendations Praised New Hepatitis B Vaccination Recommendations Praised
With hepatitis B vaccination rates low and infection rates rising, experts hope the new recommendations will raise clinician awareness and simplify screening.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 17, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

FDA Approves PreHevbrio (Hepatitis B Vaccine (Recombinant)) for the Prevention of Hepatitis B in Adults
PreHevbrio™ is the only approved 3-antigen hepatitis B vaccine for adults in the U.S. VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Panel Narrowly Backs a First-of-a-Kind COVID-19 Antiviral Pill Made By Merck
WASHINGTON (AP) — A panel of U.S. health advisers on Tuesday narrowly backed a closely watched COVID-19 pill from Merck, setting the stage for a likely authorization of the first drug that Americans could take at home to treat the coronavirus. A Food and Drug Administration (FDA) panel voted 13-10 that the drug’s benefits outweigh its risks, including potential birth defects if used during pregnancy. The recommendation came after hours of debate about the drug’s modest benefits and potential safety issues. Experts backing the treatment stressed that it should not be used by anyone who is pregnant and call...
Source: TIME: Health - November 30, 2021 Category: Consumer Health News Authors: MATTHEW PERRONE / AP Tags: Uncategorized COVID-19 wire Source Type: news

Customers who visited a New Jersey Starbucks are told to get vaccinated against hepatitis A
An employee who worked at a Starbucks location in New Jersey, has tested positive for hepatitis A and may have been exposed between November 4 and November 6 or between November 11 and 13. (Source: the Mail online | Health)
Source: the Mail online | Health - November 19, 2021 Category: Consumer Health News Source Type: news

Pfizer Says COVID-19 Pill Cuts Hospital And Death Risk By 90%
(WASHINGTON) — Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market. Currently all COVID-19 treatments used in the U.S. require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it. Pfizer said it will ask the FDA and international regulat...
Source: TIME: Health - November 5, 2021 Category: Consumer Health News Authors: Matthew Perrone/ AP Tags: Uncategorized COVID-19 wire Source Type: news

ACIP Recommends Universal HBV Vaccination for Adults Under 60 ACIP Recommends Universal HBV Vaccination for Adults Under 60
Will the universal recommendation help reinvigorate stalling declines in hepatitis B infections over the past decade?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 4, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Panel: All US adults under 60 should get hepatitis B shots
A federal advisory committee has recommended that all U.S. adults younger than 60 be vaccinated against hepatitis B (Source: ABC News: Health)
Source: ABC News: Health - November 3, 2021 Category: Consumer Health News Tags: Health Source Type: news

The Big Number: At least 27 vaccines are available in the U.S.
They include ones to prevent polio, diphtheria, hepatitis, tetanus, whooping cough, mumps, measles, the flu and other diseases. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - October 30, 2021 Category: Consumer Health News Authors: Linda Searing Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

CDC: Advisory Committee on Immunization Practices (ACIP)
Notice that the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on November 2-3, 2021. The agenda will include discussions on adult immunization schedule, child/adolescent immunization schedule, Ebola vaccine, hepatitis vaccines, Orthopoxviruses vaccine, and COVID vaccines. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required, and the meeting is open to the public, available online via a live webcast. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - October 22, 2021 Category: Rural Health Source Type: news

Public Inspection: CDC: Meetings: Advisory Committee on Immunization Practices
Pre-publication notice that the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on November 2-3, 2021. The agenda will include discussions on adult immunization schedule, child/adolescent immunization schedule, Ebola vaccine, hepatitis vaccines, Orthopoxviruses vaccine, and COVID vaccines. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required, and the meeting is open to the public, available online via a live webcast. (Source: Federal Register upda...
Source: Federal Register updates via the Rural Assistance Center - October 21, 2021 Category: Rural Health Source Type: news

Guidelines for Infection Control in the Urological Field, including Urinary Tract Management (revised second edition)
The Committee for the Development of Guidelines for Infection Control in the Urological Field, including Urinary Tract Management of the Japanese Urological Association, together with its systematic review team and external reviewers, have prepared a set of practice guidelines, an abridged version of which is published herein. These guidelines cover the following topics: (i) foundations of infection control, standard precautions, route-specific precautions, and occupational infection control (including vaccines); (ii) the relationship between urologists and infection control; (iii) infection control in urological wards and...
Source: Current Awareness Service for Health (CASH) - October 15, 2021 Category: Consumer Health News Source Type: news

Africa: Africa CDC Welcomes Historic Go-Ahead for Malaria Vaccine
[African Union] The African continent is making headway in the fight against malaria among young children. Being at the forefront in establishing, strengthening, and supporting member states in disease control and surveillance for priority diseases including HIV and AIDs, tuberculosis, malaria, COIVD-19, hepatitis, and non-communicable diseases in the region, the African Union (AU) through the Africa Centres for Disease Control and Prevention (Africa CDC) has welcomed the World Health Organization's (WHO) historic go-ahea (Source: AllAfrica News: Malaria)
Source: AllAfrica News: Malaria - October 11, 2021 Category: Infectious Diseases Source Type: news

YouTube bans all anti-vaccine misinformation
The new policy expands the rules to misleading claims about long-approved vaccines, such as those against measles and hepatitis B, as well as to falsehoods about vaccines in general. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 30, 2021 Category: Health Management Authors: Davey Alba Source Type: news

YouTube bans all anti-vaccine misinformation
The new policy expands the rules to misleading claims about long-approved vaccines, such as those against measles and hepatitis B, as well as to falsehoods about vaccines in general. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 30, 2021 Category: Biotechnology Authors: Davey Alba Source Type: news

YouTube Bans Anti-Vaccine Misinformation
The new set of policies will cover not just the Covid-19 vaccines or long-approved vaccines against diseases like measles and hepatitis B, but also general claims about vaccines, YouTube said. (Source: NYT Health)
Source: NYT Health - September 29, 2021 Category: Consumer Health News Authors: Davey Alba Tags: YouTube.com Vaccination and Immunization Rumors and Misinformation Coronavirus (2019-nCoV) Kennedy, Robert F Jr Mercola, Joseph M (1954- ) Children ' s Health Defense Social Media Source Type: news

NIAID Scientists Find a Key to Hepatitis C Entry into Cells
Understanding Structure of HCV Proteins Could Aid in Vaccine Development. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - September 21, 2021 Category: American Health Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Africa: Messenger RNA - How It Works in Nature and in Making Vaccines
[The Conversation Africa] Vaccines have long been an integral part of public health programmes around the world, reducing the spread and severity of infectious diseases. The success of immunisation strategies to protect children from diseases like polio, hepatitis B, and measles, and adults from influenza and pneumococcal disease, can be seen globally. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 7, 2021 Category: African Health Source Type: news

Estimating cost effectiveness of hepatitis B vaccination in US adults
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

Fauci:'Good Idea' to Implement School Vaccine Mandates Fauci:'Good Idea' to Implement School Vaccine Mandates
"We've done this for decades and decades, requiring polio, measles, mumps, rubella, hepatitis," he added."So this would not be something new, requiring vaccinations for children to come to school."WebMD Health News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - August 30, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Vaccine Access Negotiations to Resume as New Variants Spread
Vaccine access negotiations are at critical juncture. While many countries support the intellectual property rights waiver, including the European parliament the European Union does not. Credit: PAHO/Karen GonzálezBy Lyndal RowlandsMelbourne, Australia , Aug 30 2021 (IPS) A committee that has spent almost a year negotiating the terms of a temporary intellectual property waiver for Covid-19 medicines will reconvene in September after pausing for the European Summer. As new variants spread rapidly around the world, the deadlock in the World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRI...
Source: IPS Inter Press Service - Health - August 30, 2021 Category: International Medicine & Public Health Authors: Lyndal Rowlands Tags: COVID-19 Development & Aid Economy & Trade Featured Global Headlines Health Humanitarian Emergencies TerraViva United Nations COVAX COVID-19 vaccines TRIPS. WTO Source Type: news

Progress Toward Hepatitis B Control - World Health Organization European Region, 2016-2019
This report describes progress toward hepatitis B control in the World Health Organization European Region. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - July 29, 2021 Category: American Health Tags: Hepatitis B Hepatitis B Vaccination MMWR Morbidity & Mortality Weekly Report Source Type: news

Cameroon: 13th World Hepatitis Day - Free Screening Ongoing in Yaounde
[Cameroon Tribune] The exercise, taking place at the International Vaccination Centre ends on Friday, July 30, 2021. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 28, 2021 Category: African Health Source Type: news

Vaccine sales help GSK beat forecasts
Demand for jabs for meningitis, diphtheria and hepatitis recovers after pandemic disruption (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 28, 2021 Category: Pharmaceuticals Source Type: news

CDC: Advisory Committee on Immunization Practices (ACIP)
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on September 29-30, 2021. The agenda will include discussions on cholera vaccine, hepatitis vaccines, herpes zoster vaccines, orthopoxvirus vaccine, pneumococcal vaccine, and tickborne encephalitis vaccine. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required and the meeting is open to the public, available online via a live webcast. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - July 26, 2021 Category: Rural Health Source Type: news

European Duplicity Undermines Anti-Pandemic Efforts
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Jul 20 2021 (IPS) Despite facing the world’s worst pandemic of the last century, rich countries in the World Trade Organization (WTO) have blocked efforts to enable more affordable access to the means to fight the pandemic. Everyone knows access for all to the means for testing, treatment and prevention – including diagnostic tests, therapeutic medicines, personal protective equipment and vaccines – is crucial. Anis ChowdhuryEuropean deceit In October 2020, South Africa and India requested the WTO to temporarily suspend relevant provisions...
Source: IPS Inter Press Service - Health - July 20, 2021 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Aid Development & Aid Economy & Trade Global Headlines Health Human Rights Humanitarian Emergencies TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

New COVID-19 vaccine candidate provides effective option for low- to mid-income countries
(Emory Health Sciences) Combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and cost-effective, important aspects for vaccinating people worldwide, especially in low- to middle-income countries. Results from the study, which applied lessons learned from the hepatitis b vaccine platform technology, are published online today in Science Immunology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news

Hepatitis C vaccine could be rolled out within five years, says Nobel Prize winner who discovered virus
(European Society of Clinical Microbiology and Infectious Diseases) A vaccine to protect against infection with hepatitis C could be in use within 5 years, says Professor Sir Michael Houghton, who won the Nobel Prize for Medicine and Physiology along with three other scientists for discovering the hepatitis C virus (HCV) in 1989. Sir Michael will discuss the development of a vaccine in a special presentation at this year's European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2021 Category: International Medicine & Public Health Source Type: news

Introducing birth-dose hepatitis  B vaccination would be cost effective in Burkina Faso
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news

Hepatitis A Virus Infections Among Men Who Have Sex with Men - Eight U.S. States, 2017-2018
This report describes trends in hepatitis A cases among men who have sex with men. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - June 17, 2021 Category: American Health Tags: Diseases & Conditions Healthy Living Hepatitis A Hepatitis A Vaccination Infection MMWR Morbidity Mortality Weekly Report Outbreaks Sexual Health Source Type: news

A third dose of COVID-19 vaccine increased antibody levels in organ transplant recipients with a sub
(American College of Physicians) A case series published in Annals of Internal Medicine found that a third dose of vaccine increased antibody levels in organ transplant recipients who had suboptimal response to standard vaccination. These findings suggest that clinical trials are warranted to determine whether booster doses should be incorporated into clinical practice for transplant patients, just as they have been for hepatitis B and influenza vaccinations. This is the first study to report on response to a third vaccine dose. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 14, 2021 Category: Infectious Diseases Source Type: news

Two-dose hepatitis B vaccine cost effective versus 3-dose vaccine
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Teens Ages 12 to 15 Should Get Pfizer-BioNTech ’s COVID-19 Vaccine, Says a CDC Expert Panel
Following the US Food and Drug Administration’s decision on May 10 to extend emergency use authorization for the Pfizer-BioNTech vaccine to include 12- to 15-year olds, the Centers for Disease Control added its recommendation that teens in that age group should be vaccinated with the shot. The expert panel of the CDC’s Advisory Committee on Immunization Practices makes immunization recommendations, and determined that based on the evidence from a study of more than 2200 teens conducted by Pfizer-BioNTech, that the vaccine was safe and effective. During the day-long meeting, however, the members discussed whethe...
Source: TIME: Health - May 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Hepatitis C drugs multiply effect of COVID-19 antiviral Remdesivir
When combined with drugs currently used to treat hepatitis C, the antiviral remdesivir is 10 times more effective in treating cells infected with SARS-CoV-2, the virus that causes COVID-19. Published this week in Cell Reports, this finding - from Gaetano Montelione, a professor of chemistry and chemical biology at Rensselaer Polytechnic Institute, and his collaborators at the Icahn School of Medicine at Mount Sinai and the University of Texas at Austin - raises the potential for repurposing available drugs as COVID-19 antivirals in cases where a vaccine isn't practical or effective. (Source: World Pharma News)
Source: World Pharma News - April 27, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How DaVita is working to directly administer Covid-19 vaccines to patients across the country
The Denver-based kidney care company is using the processes it developed for flu and Hepatitis B vaccines and applying them to Covid-19. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 30, 2021 Category: American Health Authors: Jensen Werley Source Type: news

How DaVita is working to directly administer Covid-19 vaccines to patients across the country
The Denver-based kidney care company is using the processes it developed for flu and Hepatitis B vaccines and applying them to Covid-19. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 30, 2021 Category: Biotechnology Authors: Jensen Werley Source Type: news

End Vaccine Apartheid Before Millions More Die
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Mar 23 2021 (IPS) At least 85 poor countries will not have significant access to coronavirus vaccines before 2023. Unfortunately, a year’s delay will cause an estimated 2.5 million avoidable deaths in low and lower-middle income countries. As the World Health Organization (WHO) Director-General has put it, the world is at the brink of a catastrophic moral failure. Anis Chowdhury Vaccine apartheid The EU, US, UK, Switzerland, Canada and their allies continue to block the developing country proposal to temporarily suspend the World Trade Organization (W...
Source: IPS Inter Press Service - Health - March 23, 2021 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Development & Aid Economy & Trade Featured Global Headlines Health Human Rights Humanitarian Emergencies TerraViva United Nations Source Type: news

ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have madeunprecedented progress in advancing treatments and vaccines to help fight COVID-19. At this time, three vaccines and several treatments have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) with one treatment receiving FDA approval. Additional candidates under investigation have also shown promise. (Source: The Catalyst)
Source: The Catalyst - March 8, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Source Type: news

U.S. Will Have Enough COVID-19 Vaccines for All Adults by End of May, Biden Says
(WASHINGTON) — President Joe Biden said Tuesday that the U.S. expects to take delivery of enough coronavirus vaccines for all adult Americans by the end of May, two months earlier than anticipated, as his administration announced that drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved shot. With the bolstered supply, Biden also announced he would be using the powers of the federal government to direct all states to prioritize vaccinating teachers, and said the federal government would provide the doses directly through its pharmacy program. He challenged states to administe...
Source: TIME: Health - March 2, 2021 Category: Consumer Health News Authors: ZEKE MILLER, LINDA A. JOHNSON and JONATHAN LEMIRE/AP Tags: Uncategorized COVID-19 wire Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holde...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot
This article originally appeared on Akron Beacon Journal: Majority of Summit EMS workers opt out of COVID-19 vaccine ___ (c)2021 the Akron Beacon Journal (Akron, Ohio) Visit the Akron Beacon Journal (Akron, Ohio) at www.ohio.com Distributed by Tribune Content Agency, LLC. The post Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot appeared first on JEMS. (Source: JEMS Special Topics)
Source: JEMS Special Topics - January 7, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus News News Feed EMS EMT Ohio Paramedic Source Type: news